Pyxis Oncology: 10% owner GordonMD Global bought 5,517,000 shares

What happened

• The filing shows GordonMD Global Investments LP, identified as a 10% owner (investment manager for GordonMD Long Biased Master Fund LP), purchased 5,517,000 shares of Pyxis Oncology common stock on Oct 1, 2026. The filing also shows acquisition of 7,546,766 derivative securities on the same date. The filing lists the combined public offering price as $2.90 per share and accompanying Common Stock Purchase Warrant (footnote F2).

Key details

• Transaction date: Oct 1, 2026. Filing date: Oct 2, 2026.
• Price: combined public offering price $2.90 per share and accompanying warrant (footnote F2); the Form 4 reports acquisition values as N/A for the reported items.
• Shares owned after the transaction: not reported in the filing.
• Relevant footnotes from the filing:
  • F1: securities are held directly by GordonMD Long Biased Master Fund LP; GordonMD Global Investments LP serves as investment manager; Craig D. Gordon disclaims beneficial ownership except to the extent of any pecuniary interest.
  • F2: combined public offering price $2.90 per share and accompanying warrant.
  • F3: warrant exercise price $3.50, subject to adjustments.
  • F4: warrants not exercisable until issuer's stockholders approve a charter amendment and the amendment is filed and effective.
  • F5: warrants expire on the earlier of the fifth anniversary of the charter amendment effective date or the 30th calendar day following specified clinical disclosure.
• Filing timeliness: the Form 4 was filed on Oct 2, 2026 (the filing does not indicate lateness).

Why it may matter

• The filing reports a purchase by a 10% owner (a large holder, not an executive) rather than an option exercise or gift.
• The derivative securities are reported with a $3.50 exercise price and exercisability and expiration conditions tied to a charter amendment and certain clinical disclosure (footnotes F3–F5).
• A filing does not show why the insider traded or why the company acted.